

December 2020

Dear Doctor

Chronic Disease List formulary update 2021 (insulins)

We are committed to keeping doctors and their patients informed about changes to our medicine list (formulary). Since the September 2020 communication, there have been enhancements to the insulin listing on the formulary for 2021. These enhancements are written in italics, for ease of reference.

The following insulin products will be **added** to the 2021 formulary **per plan type**:

Condition	Active ingredient	Product name	Plan types
Diabetes mellitus	Insulin glargine	Optisulin cartridge – with free pen Endulin pen	All plans
	Insulin determir	Levemir cartridge – with free pen	All plans
	Insulin aspart	NovoRapid penfill – with free pen	All plans, except KeyCare

The following insulin products will be **removed** from the formulary for **all plan types** in 2021:

Condition	Deleted product	Formulary alternatives	Plan types	
Diabetes mellitus	Humulin N cartridge & KwikPen, Toujeo	Optisulin cartridge, Levemir cartridge and Endulin pen	All plans	
	pen	Basaglar cartridges	All plans, except KeyCare	
	NovoMix 30 FlexPen	Humulin 30/70 cartridge; Humalog mix 25 cartridge	All plans	
		Humalog mix 25 KwikPen	Comprehensive and Executive plans only	

Note: In 2021, Optisulin pens and Basaglar pens will no longer be available for the Comprehensive Plan and Executive Plan. Optisulin cartridges with a free reusable pen and Basaglar cartridges with a free Ergopen are alternatives, in addition to Levemir cartridges with a free pen, as required.

Discovery Health (Pty) Ltd. Registration number: 1997/013480/07. An authorised financial services provider and administrator of medical schemes. 1 Discovery Place, Sandton, 2196 | www.discovery.co.za

Directors: Dr A Ntsaluba (Chairperson), A Gore* (Group CEO), Dr J Broomberg*, H L Bosman, Dr B A Brink, S E N De Bruyn, R Farber, H D Kallner*, F N Khanyile, N S Koopowitz*, Dr T V Maphai, H P Mayers, A Pollard*, B Swartzberg*, D M Viljoen*, S V Zilwa (*Executive). Secretary: M J Botha



The table below includes the **complete 2021 insulin formulary benefit** per plan type:

Chronic Drug Amount (CDA) class name	Core, Saver and Priority Plan monthly CDA	Comprehensive and Executive Plan monthly CDA	Active ingredient	Product name	Plan types
Anti-diabetic agents:	460	515	Insulin lispro	Humalog cartridge 3 ml	All plans Comprehensive, Executive, Priority, Core, Saver, Smart and KeyCare plans
fast-acting insulins			Insulin glulisine	Apidra cartridges 3 ml	
			Insulin lispro	Humalog KwikPen 3 ml	Comprehensive, Executive, Priority, Core, Saver and Smart plans
			Insulin aspart	NovoRapid Penfill 3 ml	
			Insulin glulisine	Apidra SoloStar disposable pens 3 ml	Comprehensive and Executive plans only
Anti-diabetic agents: intermediate- or long-acting combined with fast- acting insulins (biphasic)	700	720	Insulin (human)	Humulin 30/70 cartridge 3 ml	All plans Comprehensive Executive, Priority, Core, Saver, Smart and KeyCare plans
			Insulin lispro	Humalog mix 25 cartridge 3 ml	
			Insulin lispro	Humalog mix 50 cartridge 3 ml	
			Insulin lispro	Humalog mix 25 KwikPen 3 ml	Comprehensive and Executive plans only
			Insulin lispro	Humalog mix 50 KwikPen 3 ml	



Chronic Drug Amount (CDA) class name	Core, Saver and Priority Plan monthly CDA	Comprehensive and Executive Plan monthly CDA	Active ingredient	Product name	Plan types
Anti-diabetic agents:	440	440	Insulin glargine	Optisulin cartridge 3 ml	All plans
Long-acting insulins			Insulin glargine	Endulin select pre- filled pen 3 ml	Comprehensive, Executive,
			Insulin determir	Levemir prefilled cartridge 3 ml	Priority, Core, Saver, Smart and KeyCare plans
			Insulin glargine	Basaglar cartridge 3 ml	Comprehensive, Executive, Priority, Core, Saver and Smart plans

All formulary insulin cartridges are available with free reusable pens.

For more detailed information, please view the 2021 formulary on HealthID or log on to the Healthcare Professional Zone on www.discovery.co.za and view the formulary under Tools > Forms and formularies.

Regards

Darren Sweidan Head: Health Professional Unit Strategic Risk Management Discovery Health